Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ: PLRX )

1.540 +0.020 (+1.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,321,553
Open 1.540
Bid (Size) 1.540 (1)
Ask (Size) 1.590 (12)
Prev. Close 1.520
Today's Range 1.524 - 1.600
52wk Range 1.260 - 16.52
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
What's going on in today's after hours session
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill

Performance

YTD
-88.40%
-88.40%
1 Month
-40.88%
-40.88%
3 Month
-88.88%
-88.88%
6 Month
-86.99%
-86.99%
1 Year
-89.99%
-89.99%

More News

Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
Via Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Get insights into the top gainers and losers of Monday's after-hours session.
Via Chartmill
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Here are the top movers in Monday's session.
Via Chartmill
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Which stocks are gapping on Monday?
Via Chartmill
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Unusual volume stocks in Wednesday's session
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
Via Benzinga
Exposures Fossil Fuels
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
Via Benzinga
This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
The market is filled with gapping stocks in Monday's session.
Via Chartmill
Dow Gains 100 Points; McDonald's Shares Rise After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Monday's pre-market session: top gainers and losers
Via Chartmill
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.